Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Open-Label Study of FT836, an Off-the-Shelf CAR T-Cell Therapy, With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors

NCT07216105 is registered in ClinicalTrials.gov with Fate Therapeutics as lead sponsor.

NCT NCT07216105
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07216105 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Open-Label Study of FT836, an Off-the-Shelf CAR T-Cell Therapy, With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors
Lead sponsor
Fate Therapeutics
Phase
Phase 1
Overall status
Recruiting
Start date
November 4, 2025
Completion date
January 31, 2030
Enrollment
119 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, colorectal cancer, endometrial carcinoma, head and neck squamous cell carcinoma, non-small cell lung cancer, ovarian cancer